FDA Policy/General
Senate Urged to Question Overton on FDA's Scientific Decision-Making
An upcoming Senate hearing on FDA commissioner-nominee Heidi Overton's confirmation should examine how she intends to make regulatory decisions, including her commitment to scientific evidence, transparency and established agency procedures, according to Steven Grossman, who previously held senior positions in the Senate and at HHS and is